ABD - İngilizce - NLM (National Library of Medicine)

ubi pharma inc. - caspofungin acetate (unii: vuw370o5qe) (caspofungin - unii:f0xdi6zl63) - caspofungin acetate for injection is indicated as empirical therapy for presumed fungal infections in febrile, neutropenic adult and pediatric patients (3 months of age and older) [see clinical studies (14.1, 14.5)]. caspofungin acetate for injection is indicated for the treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections in adult and pediatric patients (3 months of age and older) [see clinical studies (14.2, 14.5)]. limitations of use: caspofungin acetate for injection has not been studied in endocarditis, osteomyelitis, and meningitis due to candida . caspofungin acetate for injection is indicated for the treatment of esophageal candidiasis in adult and pediatric patients (3 months of age and older) [see clinical studies (14.3, 14.5)]. limitations of use: cas

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - caspofungin acetate, quantity: 77.7 mg - injection, powder for - excipient ingredients: mannitol; sucrose; sodium hydroxide; hydrochloric acid - caspofungin an is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - caspofungin acetate, quantity: 55.5 mg (equivalent: caspofungin, qty 50 mg) - injection, powder for - excipient ingredients: sodium hydroxide; sucrose; hydrochloric acid; mannitol - caspofungin an is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - caspofungin -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - caspofungin -

Kanada - İngilizce - Health Canada

sandoz canada incorporated - caspofungin (caspofungin acetate) - powder for solution - 50mg - caspofungin (caspofungin acetate) 50mg - echinocandins

Kanada - İngilizce - Health Canada

sandoz canada incorporated - caspofungin (caspofungin acetate) - powder for solution - 70mg - caspofungin (caspofungin acetate) 70mg - echinocandins

ABD - İngilizce - NLM (National Library of Medicine)

merck sharp & dohme llc - caspofungin acetate (unii: vuw370o5qe) (caspofungin - unii:f0xdi6zl63) - caspofungin acetate 5 mg in 1 ml - cancidas® is indicated as empirical therapy for presumed fungal infections in febrile, neutropenic adult and pediatric patients (3 months of age and older) [see clinical studies (14.1, 14.5)]. cancidas is indicated for the treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections in adult and pediatric patients (3 months of age and older) [see clinical studies (14.2, 14.5)]. limitations of use: cancidas has not been studied in endocarditis, osteomyelitis, and meningitis due to candida . cancidas is indicated for the treatment of esophageal candidiasis in adult and pediatric patients (3 months of age and older) [see clinical studies (14.3, 14.5)]. limitations of use: cancidas has not been approved for the treatment of oropharyngeal candidiasis (opc). in the study that evaluated the efficacy of caspofungin in the treatment of esophageal candidiasis, patients with concomitant opc had higher relapse rate of the opc [see clinical studies

Malta - İngilizce - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - caspofungin acetate - powder for concentrate for solution for infusion - caspofungin acetate 50 mg - antimycotics for systemic use

Malta - İngilizce - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - caspofungin acetate - powder for concentrate for solution for infusion - caspofungin acetate 70 mg - antimycotics for systemic use